Urgent Call for Global Access to Epinephrine Auto-Injectors in UK Schools to Improve Safety and Reduce Costs
A new analysis reveals that less then half of English schoolchildren at risk of life-threatening allergic reactions are prescribed epinephrine auto-injectors (AAIs), despite expert recommendations for all at-risk individuals. Archives of Disease in Childhood highlights a potential cost-saving strategy of providing “spare” AAIs to all schools, a move that could also substantially improve emergency access to this critical medication.
The research underscores a critical gap in care, wiht only 44% of schoolchildren diagnosed with food allergies receiving at least one AAI prescription, and just 34% receiving repeat prescriptions. This figure rises to 59% and 44% respectively among those who have already experienced anaphylaxis – a severe, potentially fatal allergic reaction. Experts emphasize that having two AAIs is crucial, as some reactions require multiple doses or to account for potential misuse.
Financial Implications and the Case for School-Wide Access
With approximately one in ten anaphylactic episodes occurring in schools, researchers estimate that equipping all schools with spare devices would not only enhance safety but also generate considerable savings for local health funding bodies, known as Integrated Care Boards (ICBs). Currently, many schools allow students to keep an AAI on premises in case they forget to bring their own.
Analysis of National health service (NHS) data from the 2023-24 and 2024-5 academic years revealed that nearly two-thirds (63%) of pupils prescribed AAIs were dispensed more than two devices, at an estimated cost exceeding £9 million. This suggests a significant portion of these additional AAIs are intended for school use.
Providing every school in England with four spare aais annually is estimated to cost £4.5 million. However, researchers calculate that replacing the current system of prescribing individual AAIs for school retention with a universal spare AAI program could save at least £4.6 million – representing a 25% reduction in national spending on these devices.
Legislative changes and Implementation Challenges
UK legislation was amended in 2017 to allow schools to obtain spare aais without a prescription for emergency use, notably when a student’s own device is unavailable or they haven’t been prescribed one. Despite this change, only around half of schools have adopted the practice, largely due to the high cost – frequently enough exceeding £100 per device, compared to the subsidized NHS tariff of around £10 for two.
Consequently,some ICBs have initiated pilot programs to provide spare AAIs directly to local schools. The study aimed to compare the cost-effectiveness of this approach versus continuing to prescribe AAIs on a named-patient basis for school retention. The findings strongly suggest that a centralized, school-based approach is more financially viable.
Advocacy for Systemic Change and “Benedict’s Law”
The need for systemic change is powerfully underscored by data from the National Child Mortality Database, wich reveals that 76% of fatal allergic reactions in children involve modifiable factors, including delays in administering adrenaline. Helen blythe of the Benedict Blythe Foundation, in a linked editorial, points to similar findings in Prevention of Future Death reports issued by HM Coroners.
“In the UK, we’re still shaking buckets to raise money for potentially life-saving medication in our schools,” Blythe stated, contrasting the situation with countries like Canada, which have mandated allergy safety protocols in schools for two decades.She advocates for the implementation of “Benedict’s Law,” a proposal presented to the Department for Education in 2023. This law would mandate government funding for spare AAIs in schools, comprehensive staff training in allergy awareness and emergency response, and the establishment of school-wide allergy policies.
Blythe emphasizes that regional pilots and local initiatives have already demonstrated the feasibility and financial soundness of equipping schools with AAIs,ultimately improving emergency access to adrenaline for all pupils,regardless of their individual prescription status.The researchers conclude that limiting AAI dispensing to two unexpired devices per pupil, coupled with providing spare AAIs to schools at no cost, would be a cost-neutral strategy for most ICBs and a significant step towards enhancing student safety.
